These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38859589)

  • 21. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy.
    Cheng WJ; Chen LC; Ho HO; Lin HL; Sheu MT
    Int J Nanomedicine; 2018; 13():7079-7094. PubMed ID: 30464460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A tumor microenvironment responsive biodegradable CaCO
    Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
    Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ASO Author Reflections: Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells in Cholangiocarcinoma Patients.
    Kitano Y; Baba H
    Ann Surg Oncol; 2020 Feb; 27(2):608-609. PubMed ID: 31691113
    [No Abstract]   [Full Text] [Related]  

  • 24. Stage-specificity of STING activation in intrahepatic cholangiocarcinoma determines the efficacy of its agonism.
    Luo S; Li S; Liu C; Yu D; Sun L; Zhang S; Zhao N; Zhang M; Nie J; Zhao Y; Li C; Zhang Y; Zhang Q; Meng H; Li X; Shi J; Zheng T
    Cancer Lett; 2024 Jul; 594():216992. PubMed ID: 38797231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
    Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
    BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
    Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
    Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy.
    Du L; Gong Y; Zhang X; Sun J; Gao F; Shen M; Bai H; Yang T; Cheng X; Li S; Peng J; Liu Z; Ding S; Chen J; Cheng W
    J Nanobiotechnology; 2024 Jul; 22(1):442. PubMed ID: 39068444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
    Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
    Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors.
    Ganesh S; Kim MJ; Lee J; Feng X; Ule K; Mahan A; Krishnan HS; Wang Z; Anzahaee MY; Singhal G; Korboukh I; Lockridge JA; Sanftner L; Rijnbrand R; Abrams M; Brown BD
    Mol Ther; 2024 Jun; 32(6):1895-1916. PubMed ID: 38549376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
    Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aptamer-functionalized targeted siRNA delivery system for tumor immunotherapy.
    Lv H; Wang T; Ma F; Zhang K; Gao T; Pei R; Zhang Y
    Biomed Mater; 2022 Feb; 17(2):. PubMed ID: 35147520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
    Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
    Dong Z; Liao B; Shen W; Sui C; Yang J
    Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids.
    Wen J; Qiu N; Zhu Z; Bai P; Hu M; Qi W; Liu Y; Wei A; Chen L
    Drug Deliv; 2021 Dec; 28(1):1055-1066. PubMed ID: 34078185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
    Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
    J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
    Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
    Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway.
    Thongpon P; Intuyod K; Chomwong S; Pongking T; Klungsaeng S; Muisuk K; Charoenram N; Sitthirach C; Thanan R; Pinlaor P; Pinlaor S
    Sci Rep; 2024 Jul; 14(1):16059. PubMed ID: 38992159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimuli-responsive magnetic silica-poly-lactic-co-glycolic acid hybrid nanoparticles for targeted cancer chemo-immunotherapy.
    Gupta A; Niveria K; Chandpa HH; Singh M; Kumar V; Panda AK; Meena J
    Drug Deliv Transl Res; 2024 Oct; 14(10):2712-2726. PubMed ID: 38347431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma.
    Hua S; Gu X; Jin H; Zhang X; Liu Q; Yang J
    Biomed Pharmacother; 2024 Aug; 177():117080. PubMed ID: 38972151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.